



## アッヴィについて

アッヴィのミッションは現在の深刻な健康課題を解決する革新的な医薬品の創製と提供、そして未来に向けて医療上の困難な課題に挑むことです。患者さん一人ひとりの人生を豊かなものにするため次の主要領域に取り組んでいます。免疫疾患、がん、神経疾患、アイケア、ウイルス、ウイメンズヘルス、消化器疾患、さらにアラガンエステティクスポートフォリオの製品・サービスです。アッヴィの詳細については、[www.abbvie.com](http://www.abbvie.com) をご覧ください。Twitter アカアカウント [@abbvie](https://twitter.com/abbvie)、[Facebook](https://www.facebook.com/abbvie)、[LinkedIn](https://www.linkedin.com/company/abbvie) や [Instagram](https://www.instagram.com/abbvie) でも情報を公開しています。

## Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2020 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

- 
1. Thyssen, JP, et al. Efficacy of Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Stratified Analysis from Three Phase 3 Trials by Key Baseline Characteristics. European Academy of Dermatology and Venerology Congress. 2021. P0183.
  2. Thyssen, JP, et al. Efficacy and Safety of Upadacitinib vs Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Four Body Regions - Analysis from the Heads Up Study. European Academy of Dermatology and Venerology Congress. 2021. FC01.03.
  3. Blauvelt, A, et al. Efficacy and Safety of Switching from Dupilumab to Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension Trial. European Academy of Dermatology and Venerology Congress. 2021. D1T01.3B.
  4. Guttman-Yassky E., et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind,



- randomised controlled phase 3 trials. *Lancet*. 2021; 397(10290): 2151-2168. doi:10.1016/S0140-6736(21)00588-2.
5. Reich K, Teixeira HD, Bruin-Weller, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2021; 397(10290): 2169- 2181.
  6. Blauvelt A., et al. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. *JAMA Dermatol*. Published online August 4, 2021. doi:10.1001/jamadermatol.2021.3023.
  7. RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG; September 2021. Available at: [https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf).
  8. Pipeline – Our Science | AbbVie. AbbVie. 2021. Available at: <https://www.abbvie.com/ourscience/pipeline.html>. Accessed on July 27, 2021.
  9. A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT04169373>. Accessed on July 27, 2021.
  10. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) (Measure Up 1). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03569293>. Accessed on July 27, 2021.
  11. A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy. *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03345836>. Accessed on July 27, 2021.
  12. A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02819635>. Accessed on July 27, 2021.
  13. A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone (SELECT-NEXT). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT02675426>. Accessed on July 27, 2021.
  14. A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (SELECT - PsA 1). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03104400>. Accessed on July 27, 2021.
  15. A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis (SELECT-GCA). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT03725202>. Accessed on July 27, 2021.
  16. A Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (TAK) (SELECT-TAK). *ClinicalTrials.gov*. 2021. Available at: <https://clinicaltrials.gov/ct2/show/NCT04161898>. Accessed on July 27, 2021.